E2027 (イルセンオントリン) は,フォスフォディエステラーゼ9阻害剤で,ドネペジル水塩化物と併用すると,コリナージック機能を強化する
Mai Ando1, Kazuto Yamazaki1, Eri Takahashi1
1Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
European journal of pharmacology
|September 6, 2025
まとめ
PDE9阻害剤とアセチルコリネステラス阻害剤を併用することで,認知機能障害の治療が可能である. この研究では E2027とドネペジルは 記憶力を改善し アセチルコレンのレベルを高め 新しい認知症治療法を示唆しています
科学分野:
- 神経科学
- 薬理学について
- 生物化学
背景:
- リン酸エステルゼ9 (PDE9) は,循環グアノシンモノフォスファート (cGMP) を介して神経の可塑性と記憶を調節する.
- PDE9 阻害剤 (PDE9I) は認知機能障害の治療において有望であることが示されています.
- 窒素酸化物 (NO) - cGMPのシグナル伝達はアセチルコリン (ACh) の放出に影響を与え,組み合わせ治療を示唆する.
研究 の 目的:
- PDE9I E2027 (イルセノントリン) とドネペジル水塩化物の併用効果を調査する.
- 認知障害モデルとコレリン神経機能への影響を評価する.
- 脳のACHレベルを高めるための 協同メカニズムを探求する.
主な方法:
- スコポラミンによる記憶障害の ネズミのモデルを用いた
- 新しい物体識別指数を使って 認知機能を評価した.
- 人間の誘発性多能幹細胞 (iPSC) 派生コリン神経細胞に対する試験効果.
- 細胞内cGMPと細胞外ACH値の測定
主要な成果:
- E2027とドネペジルの併用は,ドネペジルの単独治療と比較してラットモデルにおいて記憶を有意に改善した.
- 併用療法により,ラットでは海馬のACH濃度が上昇した.
- E2027 ヒトのコレリン神経細胞におけるcGMPとACHの量依存増加
- E2027とドネペジルは,細胞外AChをインビトロで相乗的に上昇させた.
結論:
- E2027とドネペジル水塩化物の組み合わせは,認知機能とACHレベルを向上させるシネージ効果を示しています.
- この組み合わせ治療は 認知症の治療戦略として 潜在的に利用できるものです
- PDE9阻害剤とアセチルコリネステラス阻害剤に関するさらなる研究は,神経変性疾患の治療に必要である.
関連する概念動画
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
820
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
820
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:26Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
645
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
645
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.1K